ESMO 2023

Preoperative checkpointinihition in ER+ disease

Remarkable efficacies in patients with HER2+ mBC with…

My highlights of ESMO23 in metastatic breast cancer

5 year follow-up

Highlights in eBC

Clearing up non-clear cell RCC

The FGFR story in bladder cancer at ESMO23

Early use of enzalutamide in advanced prostate cancer

When the history of ADC is written: Redefining…

New 3rd line therapy for RCC

Perioperativ immunotherapy for all resectable stage…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

My highlights from ESMO 2023

ALINA - immediate change of practice!

Amivantamab as a new SoC for EGFR Exon 20…

What is your definition of triple-negative breast…

New and better biomarkers are needed!

Anticipated updates and exciting new data for…

What was the most exciting news at ESMO23?

Neoadjuvant IO - is their new strategy in HR+ breast…

Our guidelines are correct

HR+ study with > 20 % PCR

Highlights in eBC

Prognostic score in early HR+/HER2-BC: translational…

Immunoncology in eBC - triple negative and more?

Preoperative checkpointinihition in ER+ disease

Negative EFS results from NeoTrip

My highlights of ESMO23 in early breast cancer

Consolidation of data in early HR+ and triple-negative…

MonarchE - trial update

New data on neoadjuvant immunotherapy

Carry-over effects in monarchE confirmed

Analysis of tumour microenvironment and…

Clinically relevant effect of pembro also in PCR

Detailed view of nodal-negative patients

ER-low corresponds diagnostically to ER-0 breast cancer

Metabolomics reveal differential expression of OMEGA 3…

5 year follow-up

Use of immunotherapy in the perioperative setting of…

Ribociclib effective in all subtypes

Studio NeoTrip: negativi i risultati

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6…

Punti salienti in eBC

Nouvelles données sur l'immunothérapie néoadjuvante

ADCs in HER2+, HER2low and TNBC - what is the future of…

What was the most exciting news at ESMO23?

How to organize a molecular tumorboards in breast…

Improvement of therapy outcome by app-based patient…

New targets, new linker, new ADCs - much more to learn…

Our guidelines are correct

Remarkable efficacies in patients with HER2+ mBC with…

Still on track for success in HER2-low MBC

Fulvestran better than anastrozole, but no survival…

Can surgery be spared following primary systemic…

New ADC in HR+ disease

T-DXd - new standard of care for brain mets?

DATO-DX - where is it going?

My highlights of ESMO23 in metastatic breast cancer

OP-1250 (Palezestrant) confirms the role of SIRDs after…

ADC + Immunotherapy - the BEGONIA study paradigm

Abemaciclib remains consistent in 5-year follow-up

HER2DX in the PHERgain trial

Patient-centered molecular medicine - a new approach

T-DXd also effective for brain metastases

Benefit for SG even after intensive pretreatment

HS20089 - a novel ADC is coming for TNBC

T-DXd in HER2+ patients with brain metastases

Improved oncological therapy with the smartphone

Dato-DXd - new player in advanced luminal disease

Even more new generation ADCs in breast cancer?

Highlights in mBC

Robust data from the monarchE

OP seems to be dispensable for super responders

Duvalumab + Dato-DXd effective

TROP2 expression as a potential mechanism of resistance…

T-DXd - nowy standard postępowania w przerzutach do…

HER2DX en el estudio PHERgain

Lo studio BEGONIA nelle paziento con tumore triplo…

La expresión de TROP2 como potencial mecanismo de…

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…

HS20089 - un nuovo ADC che si affaccia sulla scenda del…

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

Punti salienti in mBC

Targeted therapy will move forward - but more robust…

What is the future of immune therapy in prostate…

Should we use zoledronic acid in all ADT patients?

Big data and AI prediction tools

CXCR2 inhibitor in PCa

EMBARK - Quality of Life

Osteoprotection at mHSPC

Negative data for pembrolizumab in mHSCPC & mCRPC

Longterm toxicity of adjuvant RT after prostatectomy

PSMAfore unleashes urooncologic opportunity

When immunotherapy is probably not the best choice: The…

Precision medicine at mCRCP

Combination of radioligand therapy with chemotherapy…

RADICALS RT: Trial and controversies

Brave New World in mCRPC

IO therapy in metastatic prostate cancer.

PSMA FORE: Trial and controversies

Immunotherapy in metastatic PCa

TITAN: ultra-low PSA = best prognosis

Salvage radiotherapy the new standard

STAMPEDE. Bone prediction not for everyone - better…

Lu-PSMA leads forward

EMBARK expands ENZA indication to PCa

Embark without fear

ENZA P:Trial and controversies

EMBARK och livskvalitet

Immunterapi vid prostatacancer

CXCR2 hämmare och prostatacancer

Big Data och AI för prediktion vid prostatacancer

Cuando la inmunoterapia probablemente no es la mejor…

Part 2: New standard of care in first line urothelial…

Part1: New standard of care in first line urothelial…

FGFR inhibitors: What is the best scenario for this…

Amazing new data in bladder cancer

EV + Pembro as standard of care in first-line therapy…

The FGFR story in bladder cancer at ESMO23

When the history of ADC is written: Redefining…

DAD, DAD-IO

Unique bladder delivery system of gemcitabine herolds…

New SoC in firstline bladder cancer

Στιγμιότυπα για τον καρκίνο των νεφρών και της…

Inhibidores de FGFR: Cual es el mejor escenario para…

Reescribiendo la historia de una enfermedad: Nuevo…

Is de-escalating therapy ready for prime-time?

Important new treatment option but only for subset of…

Kidney cancer highlights at ESMO23

Belzutifan - whats next kidney cancer?

Belzutifan in later lines of therapy

New mode of action in mRCC - ready for prime time?

Clearing up non-clear cell RCC

New 3rd line therapy for RCC

ALINA - remarkably positive DFS in early-stage ALK+…

ALINA - immediate change of practice!

My highlights from ESMO 2023

Scene is set for inductive immunotherapy

Big improvements in early stage and a subset of…

Circulating DNA in AEGEAN trial

Neoadjuvant chemo-immunotherapy new standards in early…

ALINA - a new paradigm in operated NSCLC with…

Perioperative IO: OS-benefi from KEYNOTE-671

Perioperativ immunotherapy for all resectable stage…

Adjuvant alectinib in patients with early-stage ALK+…

Gros progrès dans les traitments medicaeux des stades…

Les points forts de l'ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion…

Perioperatieve chemo-immunotherapie voor alle patienten…

Activating EGFR-mutation - what's coming up?

ESMO2023-impact on everyday practice!

Evolving landscape of ADCs

Amivantamab at progression? MARIPOSA-2 trial

TROPION-Lung01: positive development

Treatment sequences for EGFR-mutated Patients

PAPILLON - bringing together therapy for the 1st line

Substantial improvement in rare alterations

Does immunotherapy still have a place in EGFR-positive…

MARIPOSA: Trial and controversies

Amivantamab upfront? MARIPOSA trial

Do ADCs have brain activity?

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

My highlights from ESMO 2023

Big improvements in early stage and a subset of…

Brain metastases – options to improve the systemic…

Adagrasib + pembrolizumab in patients with KRASG12C…

NRG fusions: a new drugable target?

New standard of care for metastatic EGFR exon 20…

By unanimous decision and still the champion –…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

LIBRETO - a positive study, but was it necessary?

Practice changing results on exon 20 insertion mNSCLC

MARIPOSA II: Trial and controversies

Changing treatment landscape in EGFR-mutated NSCLC

I miei punti salienti di ESMO 2023

Heeft immunotherapie nog een plek in de behandeling van…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Quelles séquences thérapeutiques pour les patients EGFR…

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

L’amivantamab, nouveau standard de traitement pour les…

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Les points forts de l'ESMO 2023

Amivantamab upfront? MARIPOSA trial

Amivantamab at progression? MARIPOSA-2 trial

A new option in relapsed SCLC

Tarlatamab in SCLC

Precision oncology in CUP

New data on H&N Cancer

PCO Therapeutics

First data on luveltamab in multiline treatment for…

New data on sarkomas

Update on gynaecological cancers